-
July 13, 2021 Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat AddictionAnthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that...
-
July 13, 2021 Wesana Health to Acquire Psychedelic Therapy and Software Company PsyTechThe deal creates Wesana Clinics, a chain of mental health facilities focused on delivering psychedelic-assisted...
-
July 12, 2021 Why Psychedelics Could Eventually Treat AsthmaResearchers continue to explore anti-inflammatory nature of psychedelics, which in small doses, may alleviate asthma...
-
July 7, 2021 Psychedelic Biotech Company Cybin Partners with Greenbrook to Develop Innovative Depression TreatmentCybin CEO says agreement "serves as a major step toward establishing a national distribution network...
-
July 6, 2021 Numinus Wellness to Acquire Neurology Centre of Toronto to Create Psychedelic Treatment FacilityNCT will utilize Numinus' expertise in psychedelic-assisted therapy to create a specialization in the application...
-
June 30, 2021 How to Become a Psychedelic FacilitatorAs psychedelic medicine gains momentum, a growing number of organizations are offering psychedelic facilitator programs....
-
June 25, 2021 First-Of-Its-Kind Ketamine Prescribing Service Now Available to PsychotherapistsA new first-of-its-kind ketamine prescribing service comes to independent psychotherapists using the dissociative with their...
-
June 23, 2021 Imperial College and Heroic Hearts Launch Psychedelic Research Retreat for Veterans with Head TraumaA new veterans research-focused psychedelic retreat in partnership between Heroic Hearts and Imperial College looks...
-
June 23, 2021 Psychedelic Educational Platform Launches Integration Therapy Survey Study to Promote Harm ReductionA new platform is aimed at psychedelic experience integration and harm reduction by surveying practitioners...
-
June 17, 2021 Extended-Release Ketamine Effective in Patients With Treatment-Resistant DepressionKetamine may offer new hope for sufferers of treatment resistant depression via an extended-release oral...
